Skip to main content
. 2019 Feb 27;3(5):718–723. doi: 10.1182/bloodadvances.2018025601

Table 1.

Patient characteristics

Recipients (n = 15)
Enrollment period January 2013 to March 2014
Age, median (range), y 52 (27-68)
Sex
 Male 11 (73.3)
 Female 4 (26.7)
Disease
 AML 6 (40)
 ALL 4 (26.7)
 MDS 1 (6.7)
 LPD 3 (20)
 PCM 1 (6.7)
Donor source
 Unrelated PBSCs 15 (100)
Conditioning
 Cy/TBI 3 (20)
 Flu/Mel 12 (80)
CMV status
 R+/D+ 6 (40)
 R+/D− 5 (33.3)
 R−/D+ 2 (13.3)
 R−/D− 2 (13.3)

Values are presented as n (%) of patients unless otherwise indicated.

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CMV, cytomegalovirus; Cy, cyclophosphamide; D, donor; Flu, fludarabine; LPD, lymphoproliferative disorder (chronic lymphocytic leukemia, Hodgkin disease, non-Hodgkin lymphoma); MDS, myelodysplastic syndrome; Mel, melphalan; PBSC, peripheral blood stem cells; PCM, plasma cell myeloma; R, recipient; TBI, total body irradiation.